The value of observational registry studies for the next infectious disease emergency

Jonathon W. Senefeld, Peter Marks, Arturo Casadevall, Michael J. Joyner

Research output: Contribution to journalEditorial


During infectious disease emergencies, it may be necessary to deploy new therapies without conclusive evidence for their effectiveness. During the SARS-CoV-2 pandemic, several countries used registries to track the use of COVID-19 convalescent plasma (CCP). Those registries provided evidence that CCP was effective when used early and with high titer.

Original languageEnglish (US)
Issue number6
Early online dateNov 8 2023
StatePublished - Dec 2023


  • clinical trials
  • coronavirus
  • neutralizing antibodies

ASJC Scopus subject areas

  • Microbiology
  • Virology

Cite this